Biomarin Pharmaceutical INC 8-K filings
NASDAQ
BioMarin Pharmaceutical Inc. announced a 28% year-over-year increase in total revenue for the third quarter of 2024 and raised its full-year guidance.
NASDAQ
BioMarin Pharmaceutical reaffirms its long-term financial guidance, including a projected $4 billion in revenue by 2027 and a mid-teen compound annual growth rate through 2034.
NASDAQ
BioMarin Pharmaceutical Inc. has entered into a credit agreement for a $600 million revolving loan facility to support working capital and general corporate needs.
NASDAQ
BioMarin Pharmaceutical Inc. will reduce its global workforce by approximately 225 employees as part of an organizational redesign and strategic shift.
NASDAQ
BioMarin Pharmaceutical Inc. has announced the retirement of its Chief R&D Officer, Dr. Henry J. Fuchs, effective March 3, 2025, with Dr. Greg Friberg set to assume the role on September 30, 2024.
NASDAQ
BioMarin Pharmaceutical Inc. announced a 20% year-over-year increase in total revenue for the second quarter of 2024 and raised its full-year guidance.
NASDAQ
BioMarin Pharmaceutical Inc. successfully held its 2024 Annual Meeting of Stockholders, electing all nominated directors and ratifying KPMG LLP as its independent auditor.
NASDAQ
BioMarin will reduce its global workforce by approximately 170 employees after a strategic review of its research and development programs.
NASDAQ
8-K: BioMarin Reports Strong Q1 2024 Results, Driven by VOXZOGO Growth and Strategic R&D Prioritization
BioMarin announced record financial results for the first quarter of 2024, highlighted by a 9% year-over-year revenue increase and a 70% jump in GAAP diluted earnings per share, driven by strong VOXZOGO sales and strategic R&D focus.
NASDAQ
BioMarin Pharmaceutical Inc. has reached a settlement in two stockholder derivative lawsuits, agreeing to implement corporate governance reforms and pay up to $1.25 million in legal fees.
NASDAQ
BioMarin announced record financial results for 2023, driven by strong sales of VOXZOGO, and provided a positive financial outlook for 2024.
NASDAQ
BioMarin Pharmaceutical Inc. announced that its Executive Vice President and Chief Commercial Officer, Jeffrey Ajer, will step down effective July 1, 2024.